C4 Therapeutics Inc Stock News

C4 Therapeutics press release (CCCC): FY GAAP EPS of -$1.82 beats by $0.27.Revenue of $45.78M (+37.9% Y/Y) beats by $12.7M.

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting –

Is it time to buy a basket of biotech stocks?

Upgrades According to Gordon Haskett, the prior rating for Williams-Sonoma Inc (NYSE:WSM) was changed from Hold to Accumulate. Williams-Sonoma earned $3.32 in the third quarter, compared to $2.56 in t

These underappreciated opportunities in healthcare are worth a closer look.

C4 Therapeutics <> announced strategic priorities and 2022 milestones to advance its targeted protein degradation portfolio.The initial Phase 1 data for CFT7455, a Novel

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that sel

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selec

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

EMC Capital Management acquired a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,619 shares of the companys stock, valued at approximately $472,000. A number of other institutional investors and hedge funds also recently modified their []

C4 Therapeutics, Inc. (NASDAQ:CCCC) Director Malcolm Salter sold 755 shares of the businesss stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $30.25, for a total transaction of $22,838.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible []

Equities research analysts forecast that C4 Therapeutics, Inc. (NASDAQ:CCCC) will post $7.16 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for C4 Therapeutics earnings. The lowest sales estimate is $4.29 million and the highest is $9.00 million. The firm is scheduled to report its next []